Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain

PHASE4CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

November 5, 2017

Primary Completion Date

November 11, 2020

Study Completion Date

November 11, 2020

Conditions
Chronic Neuropathic Pain and Fibromyalgia
Interventions
DRUG

Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992

"An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.~• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours."

Trial Locations (1)

M3B 3S6

Allevio Pain Management Clinic, Toronto

All Listed Sponsors
lead

Allevio Pain Management Clinic

OTHER

NCT04123652 - Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain | Biotech Hunter | Biotech Hunter